EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden

BACKGROUND: The development of EuroQol-5 dimensions (EQ-5D) utility over time in rheumatoid arthritis (RA) patients, treated with biologics other than tumour necrosis factor inhibitors (TNFi), based on the standard British (UK) and the new Swedish (SE) EQ-5D preference sets, has not been previously...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Arthritis Res Ther
Main Authors: Gülfe, Anders, Wallman, Johan K., Kristensen, Lars Erik
Format: Artigo
Sprog:Inglês
Udgivet: BioMed Central 2016
Fag:
Research Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4759951/
https://ncbi.nlm.nih.gov/pubmed/26892115
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-016-0950-0
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker